Obiltoxaximab
Mechanism :
Obiltoxaximab is a monoclonal antibody that binds the free protective antigen component of B. anthracis toxin thereby preventing the intracellular entry of the anthrax lethal factor and edema factor.
Indication :
- Prophylaxis & treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.
Contraindications :
No contraindications.
Dosing :
IV:
≤15 kg:
32 mg/kg/dose as a single dose.
>15 kg to 40 kg:
24 mg/kg/dose as a single dose.
>40 kg:
16 mg/kg/dose as a single dose.
Adverse Effect :
Headache, chest discomfort, chest pain, dizziness, fatigue. Skin rash, pruritus, urticarial, vomiting, lymphocytopenia, neutropenia, hypersensitivity reactions, antibody development, infusion site reaction, limb pain, increased CPK, cough, fever.
Interaction :
No known significant interactions.
Hepatic Dose :
No dosage adjustments are recommended.